Recent Updates
Recently added Catalysts
PLRX Positive Sentiment Score: 70/100

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis

Monday, September 25, 2023 1 min read
Key Takeaway: Pliant Therapeutics, Inc. will hold a conference call and webcast to discuss interim results from the INTEGRIS-PSC Phase 2a trial focused on patients with Primary Sclerosing Cholangitis. The call is scheduled for September 26, 2023, at 8:00 a.m. ET, featuring management and a principal investigator from the University of Toronto. Participants will be able to access the event via telephone or webcast, and a replay will be available on the company's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Pliant Therapeutics is hosting a conference call to discuss interim results, indicating progress in their trial.
  • The participation of a respected principal investigator may lend credibility to the findings presented.
  • The management's engagement with investors shows proactive communication and transparency.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced it will host a conference call and webcast on Tuesday, September 26, 2023 at 8:00 a.m. ET | 5:00 a.m. PT to discuss the interim results from the INTEGRIS-PSC Phase 2a trial. Members of Pliant’s management will be joined by Gideon Hirschfield, FRCP, Ph.D., Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto and a principal investigator in the INTEGRIS-PSC trial.
The conference call will be simultaneously webcast online and will be accessible from the Events & Presentation section of Pliant’s website. The live audio of the conference call can be accessed by telephone by registering in advance at the following link: Pliant Therapeutics INTEGRIS-PSC Conference Call. Upon registration, all telephone participants will receive the dial-in number along and a unique passcode to access the call. An archived replay of the webcast will be available on Pliant’s website for 60 days following completion of the event.
About Pliant Therapeutics, Inc.
Investor and Media Contact:
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.

Frequently Asked Questions

When is Pliant Therapeutics' conference call scheduled?

The conference call is on September 26, 2023, at 8:00 a.m. ET.

Who will be presenting during the conference call?

Management will be joined by Dr. Gideon Hirschfield, a principal investigator.

How can I access the conference call?

The call can be accessed via a registered telephone number or webcast.

Will a replay of the conference call be available?

Yes, an archived replay will be available for 60 days on their website.

Where can I find the webcast of the call?

The webcast can be accessed in the Events & Presentation section of Pliant's site.

Tags: PLRX Viatris Investor Conferences Healthcare Pliant Therapeutics PSC phase 2a trial interim results Gideon Hirschfield
Last updated: Sep 25, 2023